Treatment outcomes of advanced digestive well-differentiated grade 3 NETs

There is no standardized treatment for grade 3 neuroendocrine tumors (G3 NETs). We aimed to describe the treatments received in patients with advanced G3 NETs and compare their efficacy. Patients with advanced digestive G3 NETs treated between 2010 and 2018 in seven expert centers were retrospective...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine-related cancer 2021-08, Vol.28 (8), p.549-561
Hauptverfasser:	de Mestier, Louis, Lamarca, Angela, Hernando, Jorge, Zandee, Wouter, Alonso-Gordoa, Teresa, Perrier, Marine, Walenkamp, Annemiek ME, Chakrabarty, Bipasha, Landolfi, Stefania, Van Velthuysen, Marie-Louise F, Kats-Ugurlu, Gursah, Caminoa, Alejandra, Ronot, Maxime, Manoharan, Prakash, Garcia-Alvarez, Alejandro, Brabander, Tessa, García Gómez-Muriel, María Isabel, Cadiot, Guillaume, Couvelard, Anne, Capdevila, Jaume, Pavel, Marianne E, Cros, Jérôme
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adenocarcinoma - drug therapy Cancer Chemotherapy Etoposide Growth rate Humans Neuroendocrine tumors Neuroendocrine Tumors - drug therapy Neuroendocrine Tumors - pathology Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Patients Platinum Platinum - therapeutic use Retrospective Studies Somatostatin Somatostatin - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!